Parents
Sign in to add mentor| Russ Altman | grad student | 2004 | Stanford | |
| (Using machine learning to extract drug and gene relationships from text.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Seth S, Huo L, Vasaikar S, et al. (2020) Abstract P2-16-08: Longitudinal response and selection under neoadjuvant systemic therapy (NAST) in triple-negative breast cancer (TNBC): Profiling results from a randomized, TNBC enrolling trial to confirm molecular profiling improves survival (ARTEMIS; NCT02276443) Cancer Research |
| Echeverria GV, Xu M, Shao J, et al. (2020) Abstract GS4-02: Investigating genomic and phenotypic evolution of triple negative breast cancer chemoresistance and metastasis in patient-derived xenografts Cancer Research. 80 |
| Seth S, Huo L, Rauch GM, et al. (2020) Abstract 1497: Longitudinal response and selection under neoadjuvant systemic therapy (NAST) in triple-negative breast cancer (TNBC): Profiling results from a randomized trial (ARTEMIS; NCT02276443) Tumor Biology |
| Griffiths JI, Cohen AL, Jones V, et al. (2019) Opportunities for improving cancer treatment using systems biology. Current Opinion in Systems Biology. 17: 41-50 |
| Ramirez-Peña E, Arnold J, Shivakumar V, et al. (2019) The Epithelial to Mesenchymal Transition Promotes Glutamine Independence by Suppressing Expression. Cancers. 11 |
| Soundararajan R, Fradette JJ, Konen JM, et al. (2019) Targeting the Interplay between Epithelial-to-Mesenchymal-Transition and the Immune System for Effective Immunotherapy. Cancers. 11 |
| Echeverria GV, Ge Z, Seth S, et al. (2019) Resistance to neoadjuvant chemotherapy in triple-negative breast cancer mediated by a reversible drug-tolerant state. Science Translational Medicine. 11 |
| Vijay GV, Zhao N, Den Hollander P, et al. (2019) GSK3β regulates epithelial-mesenchymal transition and cancer stem cell properties in triple-negative breast cancer. Breast Cancer Research : Bcr. 21: 37 |
| Seth S, Huo L, Rauch GM, et al. (2019) Delineating longitudinal patterns of response to neoadjuvant systemic therapy (NAST) in triple-negative breast cancer (TNBC): Profiling results from a randomized, TNBC enrolling trial to confirm molecular profiling improves survival (ARTEMIS; NCT02276443). Journal of Clinical Oncology. 37: 586-586 |
| Seth S, Huo L, Rauch G, et al. (2019) Abstract P3-07-01: Towards a therapeutically relevant subtyping scheme for triple-negative breast cancer (TNBC), profiling results from A Randomized, TNBC Enrolling trial to confirm Molecular profiling Improves Survival (ARTEMIS) Cancer Research. 79 |